Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.
ANORO™ ELLIPTA™ approved as first once-daily dual bronchodilator for the treatment of COPD in the US
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved ANORO™ ELLIPTA ...
GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS®and ADVAIR® DISKUS® in patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, ...
WASHINGTON (AP) -- The Food and Drug Administration says it approved a new once-a-day inhaler from GlaxoSmithKline PLC that combines two drugs to treat lung disease. The agency cleared the Anoro ...
GlaxoSmithKline and Innovia announced new data at the American Thoracic Society (ATS) 2016 International Conference regarding the safety and efficacy of Anoro Ellipta ...
Anoro Ellipta (umeclidinium and vilanterol inhalation powder) is a combination of two bronchodilators in a single dry powder inhaler, the Ellipta. It contains umeclidinium (UMEC), a long-acting ...
LONDON — GlaxoSmithKline and Theravance on Monday announced that Anoro Ellipta (umeclidinium and vilanterol inhalation powder), a once-daily that combines two long-acting bronchodilators in a single ...
RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., April 28, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that Anoro™ Ellipta ...
TRENTON, N.J. (AP) — The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis. The FDA late Monday ...
Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.
TRENTON, N.J. (AP) - The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis. The FDA late Monday ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback